The Catalan consulting firm Genesis Biomed has opened its third office in Valencia, which adds to the one it opened four years ago in Madrid, with the purpose of applying in the biomedical sector of these communities the technology transfer model that has been successfully applied for decades in Catalonia: transform the scientific knowledge generated in universities and hospitals into patents and companies that create economic activity.
Josep Lluís Falcó, founder and CEO of the consultancy, explains that in Madrid the firm has just appointed a new director, Antonio Rodríguez Hita. “There is great potential due to the large number of companies, their turnover and the large investment in R&D,” he points out. Natalia de la Figuera, co-founder and operational director, remembers that the consultant was hired by the Community to develop the hospital spin-off plan, managed the creation of the first fruit of this process, Corify, and has now developed the technology transfer plan. of the CSIC. “In Valencia we are going to do something similar, with the advantage that there are already successful initiatives there,” says Falcó, as well as financing capacity through the Columbus Venture Partners manager of Damià Tormo and Angels Capital, the investment arm of Lanzadera. , the accelerator of Juan Roig, the founder of Mercadona.
Genesis Biomed, based in the Barcelona Science Park, has a staff of 15 professionals and plans to close the year with a turnover of 2 million euros, 25% more than in 2022, and a profit that will be around 400,000 euros. The firm, he explained, reinvests part of these surpluses through two funds it manages, with capital from Catalan family offices, to invest in biomedical companies in their most initial phase, which have already made 16 investments, three of them this year.
Since its founding in 2017, Genesis has managed 308 projects for 260 clients, more than 60 of them in 2023, and has participated in 20 financing rounds, mobilizing more than 68.5 million euros. Among the most successful projects in which the firm has participated are Anaconda Biomed (15 million raised in 2017), Oxolife (5 million raised in 2020), Corify (which is preparing a round of 9 million euros), Apta Targets (4, 5 million captured in 2017) or Peptomyc (4.2 million captured in 2017). “It is very nice to see how the projects that we have helped create are growing,” Falcó acknowledged. The firm’s next challenge, explained its founder, is internationalization that has already begun with project management in Germany, the Netherlands, Finland and Portugal.
